CD274 and central nervous system neoplasm: Although a current phase I/II study (NCT02311582) is evaluating the in situ vaccination effect of LITT using PD-L1 inhibitor pembrolizumab at varying dosages for recurrent tumors, similar trials need to be conducted for primary CNS tumors [97].